within Pharmacolibrary.Drugs.N_NervousSystem.N07X_OtherNervousSystemDrugs.N07XX08_Tafamidis;

model Tafamidis
  extends Pharmacolibrary.Drugs.ATC.N.N07XX08;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>N07XX08</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Tafamidis is a selective transthyretin (TTR) stabilizer used for the treatment of transthyretin amyloidosis (ATTR), including hereditary and wild-type forms. It prevents dissociation of the TTR tetramer, thereby inhibiting amyloid fibril formation in patients with transthyretin-mediated amyloidosis, particularly associated with polyneuropathy or cardiomyopathy. It is an approved and currently used medication.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters for healthy adult volunteers; oral single-dose of tafamidis meglumine 20 mg.</p><h4>References</h4><ol><li><p>Lee, KR, et al., &amp; Koo, TS (2018). Pharmacokinetics of tafamidis, a transthyretin amyloidosis drug, in rats. <i>Xenobiotica; the fate of foreign compounds in biological systems</i> 48(8) 831–838. DOI:<a href=&quot;https://doi.org/10.1080/00498254.2017.1366575&quot;>10.1080/00498254.2017.1366575</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28803538/&quot;>https://pubmed.ncbi.nlm.nih.gov/28803538</a></p></li><li><p>Klamerus, KJ, et al., &amp; Riley, S (2015). The effect of tafamidis on the QTc interval in healthy subjects. <i>British journal of clinical pharmacology</i> 79(6) 918–925. DOI:<a href=&quot;https://doi.org/10.1111/bcp.12561&quot;>10.1111/bcp.12561</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25546001/&quot;>https://pubmed.ncbi.nlm.nih.gov/25546001</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Tafamidis;
